Market Cap 8.37B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 13.28
Forward PE 11.98
Profit Margin 43.74%
Debt to Equity Ratio 3.00
Volume 1,704,700
Avg Vol 2,202,678
Day's Range N/A - N/A
Shares Out 117.60M
Stochastic %K 66%
Beta 1.18
Analysts Strong Sell
Price Target $76.22

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:14 AM
$HALO is currently trading at $70.03, above its 30-day moving average (MA30) of $66.91 but slightly below its 50-day moving average (MA50) of $70.27. The RSI of 71.55 indicates overbought conditions, suggesting potential for a pullback. The recent high of $79.5 and low of $63.78 over the past 60 days creates a range that can be utilized for target setting. Directional bias leans bearish in the short term due to the high RSI, indicating possible profit-taking or a correction. Suggested entry point: $69.50 (to capitalize on a potential pullback). Stop loss: $67.50 (to limit downside risk). Targets: $73.00 (first target) and $75.00 (second target) to capture potential upward movement before hitting resistance near the recent high. Monitor price action closely for confirmation of the bearish bias. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:36 AM
$HALO is currently trading at $70.03, showing a strong upward momentum with an RSI of 71.55, indicating overbought conditions. The price is above both the 30-day moving average (MA30) of 66.91 and the 50-day moving average (MA50) of 70.27, which typically suggests bullish sentiment. However, the RSI level suggests caution as it may be due for a pullback. Given the 60-day high of 79.5 and low of 63.78, the current price is closer to the high, reinforcing the potential for a correction. Suggested entry point: $68.50 (to capitalize on a potential pullback). Stop loss: $66.00 (below MA30 for risk management). Targets: $74.00 (short-term resistance) and $78.00 (approaching the 60D high). Monitor RSI for signs of reversal and adjust accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:09 AM
$HALO is currently trading at $71.19, showing a strong bullish momentum with an RSI of 78.51, indicating overbought conditions. The price is above both the 30-day MA of 66.88 and the 50-day MA of 70.37, reinforcing a bullish trend. The recent 60-day high of 79.5 suggests potential resistance, while the 60-day low of 63.78 provides a solid support level. Given the current metrics, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $70.50, just below the current price, to capture any pullback. A stop-loss should be placed at $68.00 to limit potential losses. For targets, consider $78.00 as the first target, approaching the 60-day high, and $80.00 as a second target if momentum continues. Monitor the RSI for any signs of reversal as the trade progresses. https://privateprofiteers.com
0 · Reply
JR603
JR603 Nov. 13 at 8:16 PM
$HALO While Wall street tanks, HALO is wearing a halo :) Do you suppose the Merk-y waters are starting to clear?
0 · Reply
andras1
andras1 Nov. 13 at 1:27 PM
$HALO The company just completed a $1.47B convertible bond financing, maturing in 2031 and 2032, the terms are very bullish for the company. The 2031 Convertible Notes do not bear regular interest. The 2032 Convertible Notes pay interest at an annual rate of 0.875%, with payments due semi-annually beginning May 15, 2026. Both series of notes are unsecured and may be converted into cash and, if applicable, shares of Halozyme’s common stock at the company’s election, based on a conversion rate of 11.4683 shares per $1,000 principal amount. This equates to a conversion price of approximately $87.20 per share. This implies that the bond investors have to have at least a 25% upside to break even? https://www.investing.com/news/sec-filings/halozyme-therapeutics-completes-15-billion-convertible-notes-offering-93CH-4353374 In 2022 the company did a similar deat at $1.B with the conversion price about $53.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:16 AM
$HALO is currently trading at $70.13, exhibiting a strong bullish momentum as indicated by an RSI of 72.61, suggesting it is overbought. The recent price is above the 30-day MA of 67.04 and close to the 50-day MA of 70.49, reinforcing a bullish trend. However, the high RSI indicates potential for a price correction. Given the 60-day high of $79.5 and low of $63.78, the price is nearing the upper range, which may limit upside potential in the short term. Suggested trade plan: - Entry: Consider entering a short position at $70.50 to capitalize on potential price retracement. - Stop: Set a stop-loss at $72.00 to manage risk. - Targets: First target at $67.50 (near the 30-day MA), and second target at $65.00 (near the 60-day low). Monitor market conditions closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:52 AM
$HALO is currently trading at $70.13, exhibiting a strong bullish momentum as indicated by an RSI of 72.61, suggesting it is overbought. The recent price is above the 30-day MA of 67.04 and close to the 50-day MA of 70.49, reinforcing a bullish trend. However, the high RSI indicates potential for a price correction. Given the 60-day high of $79.5 and low of $63.78, the price is nearing the upper range, which may limit upside potential in the short term. Suggested trade plan: - Entry: Consider entering a short position at $70.50 to capitalize on potential price retracement. - Stop: Set a stop-loss at $72.00 to manage risk. - Targets: First target at $67.50 (near the 30-day MA), and second target at $65.00 (near the 60-day low). Monitor market conditions closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
huma_44
huma_44 Nov. 11 at 5:39 PM
$HALO sp will be over $100 sometime in 2026, great stock to hold for long
0 · Reply
Sean29md
Sean29md Nov. 11 at 3:24 PM
$HALO Only a few weeks left in the year! Helen/Halozyme need to deliver on the promised new 2025 Enhanze deal soon.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 10 at 4:34 PM
0 · Reply
Latest News on HALO
The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 4 days ago

The Big 3: OKLO, HALO, V

OKLO V


Halozyme Just Bought Its Next Decade Of Growth

Oct 23, 2025, 1:17 PM EDT - 22 days ago

Halozyme Just Bought Its Next Decade Of Growth


Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 6 weeks ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript


Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 2 months ago

Identify Superstar Stocks Like Halozyme with Money Flows


Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Halozyme to Participate at Upcoming Investor Conferences


Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 4 months ago

Halozyme Therapeutics Added to Russell 1000® Index


Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 6 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat


Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 7 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings


Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 8 months ago

Halozyme Joins the $1 Billion Club


Halozyme: Recent Approvals Alter My Appetite

Dec 31, 2024, 2:41 AM EST - 11 months ago

Halozyme: Recent Approvals Alter My Appetite


Halozyme to Present at Upcoming Investor Conferences

Nov 27, 2024, 8:30 AM EST - 1 year ago

Halozyme to Present at Upcoming Investor Conferences


PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:14 AM
$HALO is currently trading at $70.03, above its 30-day moving average (MA30) of $66.91 but slightly below its 50-day moving average (MA50) of $70.27. The RSI of 71.55 indicates overbought conditions, suggesting potential for a pullback. The recent high of $79.5 and low of $63.78 over the past 60 days creates a range that can be utilized for target setting. Directional bias leans bearish in the short term due to the high RSI, indicating possible profit-taking or a correction. Suggested entry point: $69.50 (to capitalize on a potential pullback). Stop loss: $67.50 (to limit downside risk). Targets: $73.00 (first target) and $75.00 (second target) to capture potential upward movement before hitting resistance near the recent high. Monitor price action closely for confirmation of the bearish bias. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:36 AM
$HALO is currently trading at $70.03, showing a strong upward momentum with an RSI of 71.55, indicating overbought conditions. The price is above both the 30-day moving average (MA30) of 66.91 and the 50-day moving average (MA50) of 70.27, which typically suggests bullish sentiment. However, the RSI level suggests caution as it may be due for a pullback. Given the 60-day high of 79.5 and low of 63.78, the current price is closer to the high, reinforcing the potential for a correction. Suggested entry point: $68.50 (to capitalize on a potential pullback). Stop loss: $66.00 (below MA30 for risk management). Targets: $74.00 (short-term resistance) and $78.00 (approaching the 60D high). Monitor RSI for signs of reversal and adjust accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:09 AM
$HALO is currently trading at $71.19, showing a strong bullish momentum with an RSI of 78.51, indicating overbought conditions. The price is above both the 30-day MA of 66.88 and the 50-day MA of 70.37, reinforcing a bullish trend. The recent 60-day high of 79.5 suggests potential resistance, while the 60-day low of 63.78 provides a solid support level. Given the current metrics, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $70.50, just below the current price, to capture any pullback. A stop-loss should be placed at $68.00 to limit potential losses. For targets, consider $78.00 as the first target, approaching the 60-day high, and $80.00 as a second target if momentum continues. Monitor the RSI for any signs of reversal as the trade progresses. https://privateprofiteers.com
0 · Reply
JR603
JR603 Nov. 13 at 8:16 PM
$HALO While Wall street tanks, HALO is wearing a halo :) Do you suppose the Merk-y waters are starting to clear?
0 · Reply
andras1
andras1 Nov. 13 at 1:27 PM
$HALO The company just completed a $1.47B convertible bond financing, maturing in 2031 and 2032, the terms are very bullish for the company. The 2031 Convertible Notes do not bear regular interest. The 2032 Convertible Notes pay interest at an annual rate of 0.875%, with payments due semi-annually beginning May 15, 2026. Both series of notes are unsecured and may be converted into cash and, if applicable, shares of Halozyme’s common stock at the company’s election, based on a conversion rate of 11.4683 shares per $1,000 principal amount. This equates to a conversion price of approximately $87.20 per share. This implies that the bond investors have to have at least a 25% upside to break even? https://www.investing.com/news/sec-filings/halozyme-therapeutics-completes-15-billion-convertible-notes-offering-93CH-4353374 In 2022 the company did a similar deat at $1.B with the conversion price about $53.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:16 AM
$HALO is currently trading at $70.13, exhibiting a strong bullish momentum as indicated by an RSI of 72.61, suggesting it is overbought. The recent price is above the 30-day MA of 67.04 and close to the 50-day MA of 70.49, reinforcing a bullish trend. However, the high RSI indicates potential for a price correction. Given the 60-day high of $79.5 and low of $63.78, the price is nearing the upper range, which may limit upside potential in the short term. Suggested trade plan: - Entry: Consider entering a short position at $70.50 to capitalize on potential price retracement. - Stop: Set a stop-loss at $72.00 to manage risk. - Targets: First target at $67.50 (near the 30-day MA), and second target at $65.00 (near the 60-day low). Monitor market conditions closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:52 AM
$HALO is currently trading at $70.13, exhibiting a strong bullish momentum as indicated by an RSI of 72.61, suggesting it is overbought. The recent price is above the 30-day MA of 67.04 and close to the 50-day MA of 70.49, reinforcing a bullish trend. However, the high RSI indicates potential for a price correction. Given the 60-day high of $79.5 and low of $63.78, the price is nearing the upper range, which may limit upside potential in the short term. Suggested trade plan: - Entry: Consider entering a short position at $70.50 to capitalize on potential price retracement. - Stop: Set a stop-loss at $72.00 to manage risk. - Targets: First target at $67.50 (near the 30-day MA), and second target at $65.00 (near the 60-day low). Monitor market conditions closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
huma_44
huma_44 Nov. 11 at 5:39 PM
$HALO sp will be over $100 sometime in 2026, great stock to hold for long
0 · Reply
Sean29md
Sean29md Nov. 11 at 3:24 PM
$HALO Only a few weeks left in the year! Helen/Halozyme need to deliver on the promised new 2025 Enhanze deal soon.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 10 at 4:34 PM
0 · Reply
MyFriendsCallMeMoe
MyFriendsCallMeMoe Nov. 10 at 4:27 PM
$HALO Anyone care to share their bull case?
1 · Reply
Doozio
Doozio Nov. 8 at 8:19 PM
It was bahhht now as the correction has run its course yo slap da $HALO back on it and Roger starts rocking 🐒🍌🧠⏰♾️
0 · Reply
Sean29md
Sean29md Nov. 7 at 8:10 PM
$HALO huge volume since noon ET. On track to trade over 10% of market cap of halozyme in one afternoon. News this weekend?!
1 · Reply
kej32
kej32 Nov. 6 at 2:46 PM
$HALO This has been such easy money! This management team has been top notch. I’m not buying anymore right now but I’m not selling any either. This will be over $100 soon enough!!!
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 10:43 PM
0 · Reply
Sean29md
Sean29md Nov. 5 at 6:10 PM
$HALO Helen and Halozyme IR should pay attention to the Special Report on the impact of retail investors (today CNBC 1pm pacific) Halozyme has near zero percent retail ownership (not healthy) https://www.nasdaq.com/market-activity/stocks/halo/institutional-holdings
0 · Reply
Sean29md
Sean29md Nov. 5 at 5:36 PM
$HALO here are some concrete reasons why we need Helen to be a better storyteller: "the retail investors that are in control. That’s the conclusion from strategists across Wall Street." (See link below) Evidence that retail investors are driving market prices includes the large-scale buying seen during market dips, a disproportionate impact on specific stocks, and analysis showing that retail-heavy stocks have significantly outperformed the broader market. Outperformance of retail-favored stocks: An index of stocks most favored by individual investors surged by 30% in a recent period, significantly outperforming the S&P 500's 4.3% gain, notes http://qz.com. https://www.marketwatch.com/story/jpmorgan-barclays-and-schwab-agree-retail-investors-are-in-control-of-the-market-right-now-2a00719c?gaa_at=eafs&gaa_n=AWEtsqfSb3sXxFC6c2jDHR9bVd33euK4sI0-e3co5hA0XOXY-L0Kj6n7e_Ow&gaa_ts=690b8b44&gaa_sig=pg-EmXBZfjWmHinQvPVhB8rDCC_EhtWEV6WVADXEL1MGNaFiEtpKAwJAkrp4-g2Wb1UDnAaucPsLwh98bDaXUQ%3D%3D
0 · Reply
Sean29md
Sean29md Nov. 4 at 8:44 PM
$HALO Great quarter. Hitting it out of the ballpark over and over again. Yet, a muted market response today. We need better storytelling. Helen needs to get on Bloomberg, CNBC and investing podcasts. She is way too non-promotional. This is why Halozyme is nearly 100% institutionally owned. Near zero retail! We also need to know the name of the two HVAI partners as well as the finalization of the new Enhanze deal that she promised all year long.
1 · Reply
ZacksResearch
ZacksResearch Nov. 4 at 6:17 PM
$HALO crushed Q3 expectations — and it’s not slowing down. 🚀 Earnings and revenues both beat estimates, and the company lifted its 2025 guidance thanks to strong royalty growth — a clear sign of momentum building into next year. See what’s driving the upgraded outlook here 👉 https://www.zacks.com/stock/news/2784729/halozyme-beats-on-q3-earnings-revenues-raises-2025-view?cid=sm-stocktwits-2-2784729-teaser-19374&ADID=SYND_STOCKTWITS_TWEET_2_2784729_TEASER_19374
0 · Reply
ZacksResearch
ZacksResearch Nov. 4 at 5:17 PM
$HALO surges with Q3 earnings beat and raised 2025 guidance! 🚀 🎯 EPS of $1.72 beats the Zacks Consensus Estimate of $1.63 📈 Revenue up 22% YoY, driven by strong product sales and increased royalties 💰 2025 revenue guidance boosted, reflecting solid growth projections See what’s driving this rally 👉 https://www.zacks.com/stock/news/2784729/halozyme-beats-on-q3-earnings-revenues-raises-2025-view?cid=sm-stocktwits-2-2784729-body-19373&ADID=SYND_STOCKTWITS_TWEET_2_2784729_BODY_19373
0 · Reply
VolumePrice
VolumePrice Nov. 4 at 3:18 PM
$HALO they deliver every ER, yiu should own this stock for long
1 · Reply
VolumePrice
VolumePrice Nov. 4 at 3:17 PM
$HALO great ER, I like the management
0 · Reply